Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03602560
Recruitment Status : Completed
First Posted : July 27, 2018
Last Update Posted : July 15, 2021
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : February 16, 2020
Actual Study Completion Date : February 16, 2020